Redo TAV vs COAPT Risk Score

The Redo TAV app provides guidelines for assessing the suitability of a transcatheter aortic valve for Redo-TAV procedures using systematic CT analysis (Redo-TAV CT planning) and provides procedural guidance (Procedural Guide) for the procedure. The algorithm behind the app has been derived from extensive research of published materials on Redo-TAV procedures, including bench and CT simulation work. - Redo-TAV CT Planning After the user selects a particular valve type and size, Redo-TAV provides them with the valve's CT appearance and dimensions. Once the second valve is chosen, the app guides the user through different steps of assessment and collates the information. Using systematic step-by-step assessment, the app ensures that no aspect of assessment is missed. The app does not make recommendations to the user but simply guides them to the next step based on their choice. - Procedural Guide Based on the first valve type and size in the patient and the second valve chosen by the user, the app provides information on the height and depth of implant. When available, the app also includes a small clip of actual implant. - Procedure Data and Outcome The user is able to input important data points if desired to create a visual report.

For educational purposes and for use by medical professionals only. For patients with severe functional mitral regurgitation and symptomatic heart failure (left ventricular ejection fraction between 20-50%) despite best medical therapy. The COAPT Risk Score is a simple risk prediction tool created by combining clinical and echocardiographic variables in patients with heart failure (HF) and moderate-to-severe or severe functional mitral regurgitation (FMR) who remain symptomatic despite maximally tolerated guideline directed medical therapy (GDMT). The COAPT Risk Score provides valuable prognostic information regarding the 2-year risk of death and/or heart failure hospitalization (HFH). The score is derived from the COAPT trial population of patients with HF and moderate-to-severe or severe FMR randomized to treatment with either transcatheter edge-to-edge repair (TEER) with MitraClip plus GDMT or GDMT alone. We can incorporate TEER in the risk score and provide updated 2-year risk of death and/or HFH which can serve as a valuable shared decision-making tool for patients and physicians as well as heart teams while deciding about TEER. Created by a team of subject-matter experts including: the director of The Mount Sinai Hospital cardiac cath lab Dr. Kini, Director of Clinical and Interventional Cardiology at the Mount Sinai Health System Dr Sharma, the Mount Sinai Hospital Surgical Director Dr. Tang, COAPT Principal Investigator Dr. Stone, and COAPT Risk Score publication author Dr. Shah.